Literature DB >> 9252130

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.

F von Weizsäcker1, S Wieland, J Köck, W B Offensperger, S Offensperger, D Moradpour, H E Blum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9252130     DOI： 10.1002/hep.510260237

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  8 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

Review 2.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  [Molecular therapy in gastroenterology and hepatology].

Authors:  J Wedemeyer; N P Malek; M P Manns; M J Bahr
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

4.  VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication.

Authors:  Jun Yi; Wei-Dong Gong; Ling Wang; Rui Ling; Jiang-Hao Chen; Jun Yun
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

5.  Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Authors:  Jian Ming Fan; Qiao Zhang; Jun Xu; Sha Zhu; Tao Ke; De Fu Gao; Yu Bao Xu
Journal:  Mol Biol Rep       Date:  2007-12-05       Impact factor: 2.316

6.  Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection.

Authors:  U Protzer; M Nassal; P W Chiang; M Kirschfink; H Schaller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

7.  RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.

Authors:  Hui-Lin Wu; Li-Rung Huang; Chuan-Chuan Huang; Hsiao-Lei Lai; Chun-Jen Liu; Yu-Tzu Huang; Yun-Wei Hsu; Cheng-Yi Lu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

Review 8.  RNAi for treating hepatitis B viral infection.

Authors:  Yong Chen; Guofeng Cheng; Ram I Mahato
Journal:  Pharm Res       Date:  2007-12-12       Impact factor: 4.200
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.